Olimestra (Olmesartan Medoxomil)

Olimestra is an angiotensin II receptor blocker used in the management of cardiovascular conditions that involve the renin‑angiotensin system.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Heart failure: used as part of combination therapy to improve symptoms and outcomes.
• Diabetic nephropathy: helps slow progression of kidney damage associated with type 2 diabetes.

• Olmesartan medoxil is a pro‑drug that is rapidly converted to olmesartan, which selectively blocks the binding of angiotensin II to the AT‑1 receptors on vascular smooth‑muscle and adrenal cells. This inhibition prevents vasoconstriction and aldosterone release, leading to reduced peripheral resistance and lower blood pressure.

Adverse reactions to olmesartan are reported across a spectrum of frequency.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Nasal congestion
• Diarrhoea
• Upper respiratory tract infection

Serious or Rare Side Effects

• Angio‑edema involving the face, lips or tongue
• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Liver enzyme elevation
• Bullous pemphigoid skin disorder

Olimestra should be used with clinical oversight and patient‑specific risk assessment.

• Renal impairment: dose may need adjustment and renal function monitored.
• Hepatic impairment: use with caution; monitor liver enzymes.
• Electrolyte disturbances: watch for hyperkalaemia, especially with potassium‑sparing diuretics.
• Pregnancy: contraindicated in the second and third trimesters; avoid use.
• Concomitant NSAID therapy: may increase risk of renal dysfunction.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Olmesartan can interact with several drug classes, requiring vigilance from prescribers.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitor or another ARB): risk of severe hypotension, hyperkalaemia and renal failure.
• Potassium‑sparing diuretics or supplements: heightened risk of hyperkalaemia.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may impair renal function and blunt antihypertensive effect.
• Lithium: can increase serum lithium levels, risking toxicity.
• Cyclosporine or tacrolimus: may raise olmesartan concentrations and affect kidney function.
• Diuretics (thiazide or loop): may enhance antihypertensive effect, requiring blood pressure monitoring.